SHINE Medical Technologies, LLC, 55187-55188 [2019-22396]

Download as PDF 55187 Federal Register / Vol. 84, No. 199 / Tuesday, October 15, 2019 / Notices ADAMS accession No. Document CYAPCO Letter to NRC, ‘‘Connecticut Yankee Atomic Power Company, Haddam Neck Plant ISFSI Adoption of NAC–MPC System, Amendment 5 Certificate of Compliance and Canister Registration,’’ November 29, 2011. NRC Letter to CYAPCO, ‘‘Issuance of Exemption from NAC International Certificate of Compliance No. 1025 Fuel Specification and Loading Conditions at the Haddam Neck Power Station Independent Spent Fuel Storage Installation,’’ February 18, 2016. NRC Letter to NAC, ‘‘Certificate of Compliance for the NAC International, Inc. Multi-Purpose Canister System,’’ March 17, 2000. NRC Letter to NAC, ‘‘Amendment No. 3 to Certificate of Compliance No. 1025 for the NAC International, Inc. Multi-Purpose Canister (NAC–MPC) System,’’ October 8, 2003. NRC Letter to NAC, ‘‘Amendment No.4 to Certificate of Compliance No. 1025 for the NAC International, Inc. Multi-Purpose Canister (NAC–MPC) System,’’ October 27, 2004. NRC Letter to NAC, ‘‘Amendment No. 5 to Certificate of Compliance No. 1025 for the NAC International, Inc. Multi-Purpose Canister (NAC–MPC) System,’’ September 19, 2007. V. Conclusion Week of October 28, 2019—Tentative Based on the foregoing considerations, the NRC staff has determined that, pursuant to § 72.7, the exemption is authorized by law, will not endanger life or property or the common defense and security, and is otherwise in the public interest. Therefore, the NRC grants the licensee an exemption from the requirements of § 72.212(a)(2), § 72.212(b)(3), § 72.212(b)(5)(i), § 72.212(b)(11), and § 72.214 only with regard to meeting Appendix A, TS A.5.1 of CoC No. 1025. This exemption is effective upon issuance. Tuesday, October 29, 2019 10:00 a.m. Transformation at the NRC—Becoming a Modern, RiskInformed Regulator (Public Meeting); (Contact: Alysia Bone: 301–415–1034). Dated at Rockville, Maryland, this 9th day of October, 2019. For the Nuclear Regulatory Commission. John B. McKirgan, Chief, Spent Fuel Licensing Branch, Division of Spent Fuel Management, Office of Nuclear Material Safety and Safeguards. [FR Doc. 2019–22406 Filed 10–11–19; 8:45 am] BILLING CODE 7590–01–P NUCLEAR REGULATORY COMMISSION [NRC–2019–0001] Sunshine Act Meetings Weeks of October 14, 21, 28, November 4, 11, 18, 2019. TIME AND DATE: Commissioners’ Conference Room, 11555 Rockville Pike, Rockville, Maryland. PLACE: khammond on DSKJM1Z7X2PROD with NOTICES STATUS: Public and Closed. Week of October 14, 2019 There are no meetings scheduled for the week of October 14, 2019. Week of October 21, 2019—Tentative There are no meetings scheduled for the week of October 21, 2019. VerDate Sep<11>2014 16:25 Oct 11, 2019 Jkt 250001 Week of November 4, 2019—Tentative There are no meetings scheduled for the week of November 4, 2019. Week of November 11, 2019—Tentative There are no meetings scheduled for the week of November 11, 2019. Week of November 18, 2019—Tentative There are no meetings scheduled for the week of November 18, 2019. CONTACT PERSON FOR MORE INFORMATION: For more information or to verify the status of meetings, contact Denise McGovern at 301–415–0681 or via email at Denise.McGovern@nrc.gov. The schedule for Commission meetings is subject to change on short notice. The NRC Commission Meeting Schedule can be found on the internet at: https://www.nrc.gov/public-involve/ public-meetings/schedule.html. The NRC provides reasonable accommodation to individuals with disabilities where appropriate. If you need a reasonable accommodation to participate in these public meetings or need this meeting notice or the transcript or other information from the public meetings in another format (e.g., braille, large print), please notify Anne Silk, NRC Disability Program Specialist, at 301–287–0745, by videophone at 240–428–3217, or by email at Anne.Silk@nrc.gov. Determinations on requests for reasonable accommodation will be made on a case-by-case basis. Members of the public may request to receive this information electronically. If you would like to be added to the distribution, please contact the Nuclear Regulatory Commission, Office of the Secretary, Washington, DC 20555 (301– PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 ML11348A106 ML16055A161 ML003704040 ML032820200 ML043020224 ML072700041 415–1969), or by email at Tyesha.Bush@ nrc.gov. The NRC is holding the meetings under the authority of the Government in the Sunshine Act, 5 U.S.C. 552b. Dated at Rockville, Maryland, this 10th day of October 2019. For the Nuclear Regulatory Commission. Denise L. McGovern, Policy Coordinator, Office of the Secretary. [FR Doc. 2019–22552 Filed 10–10–19; 4:15 pm] BILLING CODE 7590–01–P NUCLEAR REGULATORY COMMISSION [Docket No. 50–608; NRC–2019–0173] SHINE Medical Technologies, LLC Nuclear Regulatory Commission. ACTION: Operating license application; acceptance for docketing. AGENCY: The U.S. Nuclear Regulatory Commission (NRC) staff accepts and dockets an application submitted by SHINE Medical Technologies, LLC (SHINE), dated July 17, 2019, filed pursuant to the Atomic Energy Act of 1954, as amended, and the NRC’s regulations, for an operating license for the SHINE Medical Isotope Production Facility. DATES: This action takes effect on October 15, 2019. ADDRESSES: Please refer to Docket ID NRC–2019–0173 when contacting the NRC about the availability of information for this action. You may obtain publicly-available information related to this action by any of the following methods: • Federal Rulemaking Website: Go to https://www.regulations.gov/ and search for Docket ID NRC–2019–0173. Address questions about NRC docket IDs in Regulations.gov to Anne Frost; telephone: 301–287–9232; email: Anne.Frost@nrc.gov. For technical SUMMARY: E:\FR\FM\15OCN1.SGM 15OCN1 khammond on DSKJM1Z7X2PROD with NOTICES 55188 Federal Register / Vol. 84, No. 199 / Tuesday, October 15, 2019 / Notices questions, contact the individual listed in the FOR FURTHER INFORMATION CONTACT section of this document. • NRC’s Agencywide Documents Access and Management System (ADAMS): You may obtain publiclyavailable documents online in the ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/ adams.html. To begin the search, select ‘‘Begin Web-based ADAMS Search.’’ For problems with ADAMS, please contact the NRC’s Public Document Room (PDR) reference staff at 1–800–397–4209, 301– 415–4737, or by email to pdr.resource@ nrc.gov. The ADAMS accession number for each document referenced (if it is available in ADAMS) is provided the first time that it is mentioned in this document. • NRC’s PDR: You may examine and purchase copies of public documents at the NRC’s PDR, Room O1–F21, One White Flint North, 11555 Rockville Pike, Rockville, Maryland 20852. FOR FURTHER INFORMATION CONTACT: Steven T. Lynch, Office of Nuclear Reactor Regulation, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001, telephone: 301–415– 1524; email: Steven.Lynch@nrc.gov. SUPPLEMENTARY INFORMATION: By letter dated July 17, 2019 (ADAMS Accession No. ML19211C044), SHINE filed with the NRC, pursuant to Section 103 of the Atomic Energy Act and part 50, ‘‘Domestic Licensing of Production and Utilization Facilities,’’ of title 10 of the Code of Federal Regulations (10 CFR), an application for an operating license for the SHINE Medical Isotope Production Facility to be located in Janesville, Wisconsin (ADAMS Package Accession No. ML19211C143). A notice of receipt and availability of this application was previously published in the Federal Register on September 10, 2019 (84 FR 47557). SHINE has proposed to construct and operate a facility in Janesville, Wisconsin for the production of molybdenum-99 (Mo-99) through the irradiation and processing of a uranyl sulfate solution. As described in the operating license application, the proposed facility would comprise an irradiation facility and radioisotope production facility. The irradiation facility would consist of eight subcritical operating assemblies (or irradiation units), which would each be licensed as a utilization facility, as defined in 10 CFR 50.2, ‘‘Definitions,’’ and supporting structures, systems, and components (SSCs) for the irradiation of low enriched uranium. The radioisotope production facility would consist of hot cell structures, licensed collectively as a VerDate Sep<11>2014 16:25 Oct 11, 2019 Jkt 250001 production facility, as defined in 10 CFR 50.2, and associated SSCs for the processing of irradiated material and extraction and purification of Mo-99. The irradiation facility and radioisotope production facility are collectively referred to as the SHINE Medical Isotope Production Facility. Issuance of the operating license would authorize the applicant to operate the SHINE Medical Isotope Production Facility for a 30-year period. By letters dated March 26 and May 31, 2013 (ADAMS Accession Nos. ML13088A192 and ML13172A361, respectively), SHINE (at the time known as SHINE Medical Technologies, Inc.) submitted a two-part construction permit application, as updated in 2015, for its eight utilization facilities and one production facility (ADAMS Package Accession No. ML15258A431). The NRC issued Construction Permit No. CPMIF– 001 to SHINE on February 29, 2016 (ADAMS Package Accession No. ML16041A473), as supported by NUREG–2189, ‘‘Safety Evaluation Report Related to SHINE Medical Technologies, Inc. Construction Permit Application for a Medical Radioisotope Production Facility,’’ dated August 2016, (ADAMS Accession No. ML16229A140) and NUREG–2183, ‘‘Environmental Impact Statement for the Construction Permit for the SHINE Medical Radioisotope Production Facility,’’ dated October 2015 (ADAMS Accession No. ML15288A046). In accordance with 10 CFR part 2, ‘‘Agency Rules of Practice and Procedure,’’ and part 50, the NRC staff performed an acceptance review of the SHINE operating license application and, by letter dated October 8, 2019 (ADAMS Accession No. ML19276D411), concluded that the application is acceptable for docketing under Docket Number 50–608. As part of a detailed technical review of the SHINE application, the NRC staff will prepare and document its findings in a safety evaluation report. Additionally, in accordance with 10 CFR part 51, ‘‘Environmental Protection Regulations for Domestic Licensing and Related Regulatory Functions,’’ the NRC staff will also prepare a supplemental environmental impact statement for the proposed action. Following additional interactions with SHINE, the NRC staff will establish a review schedule that identifies significant milestones and expected review completion date. Docketing of the application does not preclude the NRC staff from requesting additional information from SHINE as the review proceeds, nor does it predict whether PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 the Commission will grant or deny the operating license. The application will be referred to the Advisory Committee on Reactor Safeguards for review and report, which will be provided to the Commission in accordance with 10 CFR 50.58, ‘‘Hearings and report of the Advisory Committee on Reactor Safeguards.’’ If the Commission finds that the SHINE operating license application meets the applicable standards of the Atomic Energy Act and the Commission’s regulations, and that required notifications to other agencies and bodies have been made, the Commission will issue an operating license containing conditions and limitations that the Commission finds appropriate and necessary. In accordance with the provisions of 10 CFR 2.105, ‘‘Notice of proposed action,’’ a separate notice of opportunity to file a petition for leave to intervene in a hearing will be published at a later date. Dated at Rockville, Maryland, this 8th day of October, 2019. For the Nuclear Regulatory Commission. Steven T. Lynch, Project Manager, Research and Test Reactors Licensing Branch, Division of Licensing Projects, Office of Nuclear Reactor Regulation. [FR Doc. 2019–22396 Filed 10–11–19; 8:45 am] BILLING CODE 7590–01–P OFFICE OF SPECIAL COUNSEL [OMB Control No. 3255–0005] Form OSC–14 Office of Special Counsel. Notice of information collection; request for comments. AGENCY: ACTION: In accordance with the Paperwork Reduction Act of 1995, Office of Management and Budget (OMB) implementing regulations, and the Government Paperwork Elimination Act, the U.S. Office of Special Counsel (OSC) is seeking comments on renewal of OMB’s approval of OSC’s updated, dynamic electronic form used to file complaints and disclosures with OSC. The form, known as Form OSC–14, was approved by OMB in September 2017. OSC revised Form OSC–14 in July 2019 to reflect subsequent statutory changes and obtained emergency OMB/OIRA approval of the updated information collection. The final rule authorizing use of Form OSC–14 went into effect on August 26, 2019 and the information collection is currently authorized by OMB Control Number 3255–0005, SUMMARY: E:\FR\FM\15OCN1.SGM 15OCN1

Agencies

[Federal Register Volume 84, Number 199 (Tuesday, October 15, 2019)]
[Notices]
[Pages 55187-55188]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-22396]


-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[Docket No. 50-608; NRC-2019-0173]


SHINE Medical Technologies, LLC

AGENCY: Nuclear Regulatory Commission.

ACTION: Operating license application; acceptance for docketing.

-----------------------------------------------------------------------

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) staff accepts and 
dockets an application submitted by SHINE Medical Technologies, LLC 
(SHINE), dated July 17, 2019, filed pursuant to the Atomic Energy Act 
of 1954, as amended, and the NRC's regulations, for an operating 
license for the SHINE Medical Isotope Production Facility.

DATES: This action takes effect on October 15, 2019.

ADDRESSES: Please refer to Docket ID NRC-2019-0173 when contacting the 
NRC about the availability of information for this action. You may 
obtain publicly-available information related to this action by any of 
the following methods:
     Federal Rulemaking Website: Go to https://www.regulations.gov/ and search for Docket ID NRC-2019-0173. Address 
questions about NRC docket IDs in Regulations.gov to Anne Frost; 
telephone: 301-287-9232; email: [email protected]. For technical

[[Page 55188]]

questions, contact the individual listed in the FOR FURTHER INFORMATION 
CONTACT section of this document.
     NRC's Agencywide Documents Access and Management System 
(ADAMS): You may obtain publicly-available documents online in the 
ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/adams.html. To begin the search, select ``Begin Web-based ADAMS 
Search.'' For problems with ADAMS, please contact the NRC's Public 
Document Room (PDR) reference staff at 1-800-397-4209, 301-415-4737, or 
by email to [email protected]. The ADAMS accession number for each 
document referenced (if it is available in ADAMS) is provided the first 
time that it is mentioned in this document.
     NRC's PDR: You may examine and purchase copies of public 
documents at the NRC's PDR, Room O1-F21, One White Flint North, 11555 
Rockville Pike, Rockville, Maryland 20852.

FOR FURTHER INFORMATION CONTACT: Steven T. Lynch, Office of Nuclear 
Reactor Regulation, U.S. Nuclear Regulatory Commission, Washington, DC 
20555-0001, telephone: 301-415-1524; email: [email protected].

SUPPLEMENTARY INFORMATION: By letter dated July 17, 2019 (ADAMS 
Accession No. ML19211C044), SHINE filed with the NRC, pursuant to 
Section 103 of the Atomic Energy Act and part 50, ``Domestic Licensing 
of Production and Utilization Facilities,'' of title 10 of the Code of 
Federal Regulations (10 CFR), an application for an operating license 
for the SHINE Medical Isotope Production Facility to be located in 
Janesville, Wisconsin (ADAMS Package Accession No. ML19211C143). A 
notice of receipt and availability of this application was previously 
published in the Federal Register on September 10, 2019 (84 FR 47557).
    SHINE has proposed to construct and operate a facility in 
Janesville, Wisconsin for the production of molybdenum-99 (Mo-99) 
through the irradiation and processing of a uranyl sulfate solution. As 
described in the operating license application, the proposed facility 
would comprise an irradiation facility and radioisotope production 
facility. The irradiation facility would consist of eight subcritical 
operating assemblies (or irradiation units), which would each be 
licensed as a utilization facility, as defined in 10 CFR 50.2, 
``Definitions,'' and supporting structures, systems, and components 
(SSCs) for the irradiation of low enriched uranium. The radioisotope 
production facility would consist of hot cell structures, licensed 
collectively as a production facility, as defined in 10 CFR 50.2, and 
associated SSCs for the processing of irradiated material and 
extraction and purification of Mo-99. The irradiation facility and 
radioisotope production facility are collectively referred to as the 
SHINE Medical Isotope Production Facility. Issuance of the operating 
license would authorize the applicant to operate the SHINE Medical 
Isotope Production Facility for a 30-year period.
    By letters dated March 26 and May 31, 2013 (ADAMS Accession Nos. 
ML13088A192 and ML13172A361, respectively), SHINE (at the time known as 
SHINE Medical Technologies, Inc.) submitted a two-part construction 
permit application, as updated in 2015, for its eight utilization 
facilities and one production facility (ADAMS Package Accession No. 
ML15258A431). The NRC issued Construction Permit No. CPMIF-001 to SHINE 
on February 29, 2016 (ADAMS Package Accession No. ML16041A473), as 
supported by NUREG-2189, ``Safety Evaluation Report Related to SHINE 
Medical Technologies, Inc. Construction Permit Application for a 
Medical Radioisotope Production Facility,'' dated August 2016, (ADAMS 
Accession No. ML16229A140) and NUREG-2183, ``Environmental Impact 
Statement for the Construction Permit for the SHINE Medical 
Radioisotope Production Facility,'' dated October 2015 (ADAMS Accession 
No. ML15288A046).
    In accordance with 10 CFR part 2, ``Agency Rules of Practice and 
Procedure,'' and part 50, the NRC staff performed an acceptance review 
of the SHINE operating license application and, by letter dated October 
8, 2019 (ADAMS Accession No. ML19276D411), concluded that the 
application is acceptable for docketing under Docket Number 50-608.
    As part of a detailed technical review of the SHINE application, 
the NRC staff will prepare and document its findings in a safety 
evaluation report. Additionally, in accordance with 10 CFR part 51, 
``Environmental Protection Regulations for Domestic Licensing and 
Related Regulatory Functions,'' the NRC staff will also prepare a 
supplemental environmental impact statement for the proposed action.
    Following additional interactions with SHINE, the NRC staff will 
establish a review schedule that identifies significant milestones and 
expected review completion date. Docketing of the application does not 
preclude the NRC staff from requesting additional information from 
SHINE as the review proceeds, nor does it predict whether the 
Commission will grant or deny the operating license.
    The application will be referred to the Advisory Committee on 
Reactor Safeguards for review and report, which will be provided to the 
Commission in accordance with 10 CFR 50.58, ``Hearings and report of 
the Advisory Committee on Reactor Safeguards.'' If the Commission finds 
that the SHINE operating license application meets the applicable 
standards of the Atomic Energy Act and the Commission's regulations, 
and that required notifications to other agencies and bodies have been 
made, the Commission will issue an operating license containing 
conditions and limitations that the Commission finds appropriate and 
necessary.
    In accordance with the provisions of 10 CFR 2.105, ``Notice of 
proposed action,'' a separate notice of opportunity to file a petition 
for leave to intervene in a hearing will be published at a later date.

    Dated at Rockville, Maryland, this 8th day of October, 2019.

    For the Nuclear Regulatory Commission.
Steven T. Lynch,
Project Manager, Research and Test Reactors Licensing Branch, Division 
of Licensing Projects, Office of Nuclear Reactor Regulation.
[FR Doc. 2019-22396 Filed 10-11-19; 8:45 am]
 BILLING CODE 7590-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.